YORVIPATH (Specialised Therapeutics Pharma Pty Ltd)
Product name
YORVIPATH
Date registered
Evaluation commenced
Decision date
Approval time
150 (255 working days)
Active ingredients
palopegteriparatide
Registration type
NCE/ NBE
Indication
Yorvipath (palopegteriparatide) is a parathyroid hormone (PTH) analogue indicated for the treatment of chronic hypoparathyroidism in adults.